These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36052126)

  • 1. Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
    Li Q; Qiao J; Jin H; Chen B; He Z; Wang G; Ni X; Wang M; Xia M; Li B; Chen R; Hu P
    Front Pharmacol; 2022; 13():966176. PubMed ID: 36052126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
    Jiang C; Zhou H; Zhang W; Xia Y; Li B; Ni X; Wang G; Zhang W; Chen B; He Z; Zhang M; Chen R; Jin H; Deng L
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):555-567. PubMed ID: 36566344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
    Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
    J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6.
    Tang X; Zeng X; Guan X; Chen R; Hu P
    Front Pharmacol; 2021; 12():617265. PubMed ID: 33679400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Jackson K; Chua L; Velez de Mendizabal N; Pitou C; Rodriguez Capriles C; Paller AS; Lansang P; Seyger MMB; Papp K;
    Br J Clin Pharmacol; 2022 Mar; 88(3):1074-1086. PubMed ID: 34378230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
    Timmermann S; Hall A
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.
    Tham LS; Tang CC; Choi SL; Satterwhite JH; Cameron GS; Banerjee S
    J Clin Pharmacol; 2014 Oct; 54(10):1117-24. PubMed ID: 24752880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357.
    Ooi QX; Kristoffersson A; Korell J; Flack M; L Plan E; Weber B
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):758-769. PubMed ID: 36919398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
    Bruin G; Loesche C; Nyirady J; Sander O
    J Clin Pharmacol; 2017 Jul; 57(7):876-885. PubMed ID: 28273356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
    Tran L; Yao Z; Xu Z; Vermeulen A
    Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
    Croxtall JD
    Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.
    Maier CS; Eckert D; Laroux FS; Hew KM; Suleiman AA; Liu W; Mohamed MF
    Clin Pharmacol Drug Dev; 2024 May; 13(5):474-484. PubMed ID: 38231873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.